Researchers wanted to understand how a medication called cilostazol helps prevent strokes from happening again. They looked at patients who had already experienced a noncardioembolic ischemic stroke, which is a type of stroke not caused by a heart clot. The study involved 889 patients taking cilostazol plus another blood thinner and 906 patients taking only one blood thinner.
The main finding was that patients taking cilostazol had fewer repeat strokes. About 3% of patients on the dual therapy had another stroke, compared to about 6.8% of patients on single therapy. The analysis specifically showed that this benefit did not appear to work by lowering systolic blood pressure, which is the top number in a blood pressure reading.
It is important to know this was a post hoc analysis. This means researchers went back and looked at data from a previous study that was designed to answer a different question. While the results are interesting, they need to be confirmed by studies specifically designed to test this idea. The analysis did not report on side effects or safety concerns from adding cilostazol.
Readers should understand this research helps explain how an existing medication might work, but it does not change current medical practice. The finding suggests cilostazol's benefit for preventing another stroke may come from a mechanism other than blood pressure control. More research is needed to fully understand this process.
